ERNA (Ernexa Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)


ERNA Ernexa Therapeutics Inc ERNA
30 GF Score
Price $6.65
! 4 Warning Signs
View Full Analysis

What is Ernexa Therapeutics Net Margin %?

Ernexa Therapeutics ERNA +6.74% 30 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 947 Biotechnology companies, Ernexa Therapeutics ranks worse than 105596.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Ernexa Therapeutics's Net Income for the three months ended in Mar. 2026 was $-5.51 Mil. Ernexa Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Ernexa Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Ernexa Therapeutics's Net Margin % or its related term are showing as below:


ERNA's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Ernexa Therapeutics  (NAS:ERNA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Ernexa Therapeutics Net Margin % Related Terms

Ernexa Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Ernexa Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ernexa Therapeutics Net Margin % Chart

Ernexa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 -31,864.71 -7,652.75 0.00

Ernexa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ERNA vs KPRX, PHGE, BRTX: Net Margin % Comparison

For the Biotechnology subindustry, Ernexa Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ernexa Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ernexa Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Ernexa Therapeutics's Net Margin % falls into.


ERNA
30GF Score
Ernexa Therapeutics Inc ERNA
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ernexa Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Ernexa Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-14.084/0
= %

Ernexa Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-5.506/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Ernexa Therapeutics (ERNA) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Ernexa Therapeutics and its competitors. According to the industry distribution chart, Ernexa Therapeutics ranks #999999 out of 947 companies in the Biotechnology industry.
Is Ernexa Therapeutics' Net Margin % too high?
Ernexa Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Ernexa Therapeutics ranks #999999 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' Net Margin % compare to KPRX and PHGE?
According to the Biotechnology industry distribution chart, Ernexa Therapeutics ranks #999999 out of 947 companies for Net Margin %. This places Ernexa Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ernexa Therapeutics and its competitors. Ernexa Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ernexa Therapeutics Business Description

Address 1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score

Get the complete analysis for ERNA

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.65
Price